A coordination model for enhancing research on rare diseases

Michela Chessa, Vito Fragnelli () and Stefano Gagliardo ()
Additional contact information
Vito Fragnelli: University of Eastern Piedmont
Stefano Gagliardo: University of Genova

Chapter Chapter 4 in Advanced Decision Making Methods Applied to Health Care, 2012, pp 51-66 from Springer

Abstract: Abstract Rare diseases affect a great number of patients that suffer of the non existence of effective cures. Medical products for prevention, diagnosis or treatment of this kind of disorders are called orphan drugs and pharmaceutical industries have not a great interest under normal market conditions in developing and marketing products for a small number of patients. The Orphan Drug Act and the Regulation on Orphan Medicinal Products played a relevant role in encouraging the development of new orphan drugs, as in America as in Europe. In this chapter we propose that pharmaceutical industries coordinate their researches in order to avoid that two or more of them study a new molecule for the same disease, with the aim of further enhancing the research on rare diseases.

Keywords: rare disease; orphan drug; multiple knapsack problem; college admissions problem (search for similar items in EconPapers)
Date: 2012
References: Add references at CitEc
Citations:

There are no downloads for this item, see the EconPapers FAQ for hints about obtaining it.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:isochp:978-88-470-2321-5_4

Ordering information: This item can be ordered from
http://www.springer.com/9788847023215

DOI: 10.1007/978-88-470-2321-5_4

Access Statistics for this chapter

More chapters in International Series in Operations Research & Management Science from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().